MX2008012399A - Modulacion de cinasa de ceramida. - Google Patents

Modulacion de cinasa de ceramida.

Info

Publication number
MX2008012399A
MX2008012399A MX2008012399A MX2008012399A MX2008012399A MX 2008012399 A MX2008012399 A MX 2008012399A MX 2008012399 A MX2008012399 A MX 2008012399A MX 2008012399 A MX2008012399 A MX 2008012399A MX 2008012399 A MX2008012399 A MX 2008012399A
Authority
MX
Mexico
Prior art keywords
ring
ceramide kinase
proviso
branched
aromatic
Prior art date
Application number
MX2008012399A
Other languages
English (en)
Inventor
Berndt Oberhauser
Frederic Bornancin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2008012399A publication Critical patent/MX2008012399A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Un compuesto de la Fórmula (I): (ver fórmula I) en donde R1 es un grupo alifático, aromático, o heterocíclico de cadena recta, ramificada, o cíclica, que comprende cuando menos 8 átomos de carbono, por ejemplo de 8 a 22; R2 es un grupo alifático, aromático, o heterocíclico de cadena recta, ramificada, o cíclica, que comprende de 1 a 12 átomos de carbono; y el anillo A es heterociclilo fusionado con el anillo de fenilo con el que está unido el anillo A, que comprende 5 6 6 miembros del anillo, y de 1 a 4 heteroátomos seleccionados a partir de N, S, O; en donde se excluyen ciertos compuestos por condición; y el uso de estos compuestos sin condición como productos farmacéuticos en los trastornos que son mediados por la cinasa de ceramida.
MX2008012399A 2006-03-30 2007-03-28 Modulacion de cinasa de ceramida. MX2008012399A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0606429.9A GB0606429D0 (en) 2006-03-30 2006-03-30 Organic compounds
PCT/EP2007/002765 WO2007112914A2 (en) 2006-03-30 2007-03-28 Ceramide kinase modulation

Publications (1)

Publication Number Publication Date
MX2008012399A true MX2008012399A (es) 2008-10-09

Family

ID=36424929

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008012399A MX2008012399A (es) 2006-03-30 2007-03-28 Modulacion de cinasa de ceramida.

Country Status (12)

Country Link
US (1) US20090170914A1 (es)
EP (1) EP2004617A2 (es)
JP (1) JP2009531365A (es)
KR (1) KR20080098443A (es)
CN (1) CN101415695A (es)
AU (1) AU2007234022A1 (es)
BR (1) BRPI0709270A2 (es)
CA (1) CA2644636A1 (es)
GB (1) GB0606429D0 (es)
MX (1) MX2008012399A (es)
RU (1) RU2008142834A (es)
WO (1) WO2007112914A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US9499790B2 (en) 2010-08-26 2016-11-22 Kyoto University Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells
EP2610249B1 (en) * 2010-08-26 2017-10-11 Kyoto University Pluripotent stem cell cardiomyocyte differentiation-promoting agent
WO2012029994A1 (en) * 2010-09-02 2012-03-08 Kyoto University Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
KR101996343B1 (ko) 2012-01-27 2019-07-05 고쿠리츠 다이가쿠 호진 교토 다이가쿠 전능성 줄기세포의 심근분화 유도방법
WO2014136519A1 (ja) 2013-03-08 2014-09-12 国立大学法人京都大学 Ｅｇｆ受容体阻害剤を含む多能性幹細胞の心筋分化促進剤
PT3466955T (pt) 2014-01-13 2021-01-29 Aurigene Discovery Tech Ltd Método de preparação de derivados de oxazolo[4,5-b] piridina e tiazolo[4,5-b] piridina como inibidores de irak-4 para o tratamento do cancro
JP6651218B2 (ja) 2014-05-30 2020-02-19 国立大学法人京都大学 低分子化合物を用いた多能性幹細胞の心筋分化誘導法
EA201890308A1 (ru) * 2015-07-15 2018-08-31 Ориджин Дискавери Текнолоджиз Лимитед Замещенные азасоединения как ингибиторы irak-4
JP6984854B2 (ja) * 2015-10-08 2021-12-22 国立大学法人千葉大学 ニーマン・ピック病ｃ型を予防または治療するための医薬組成物
HRP20230657T8 (hr) 2017-03-31 2023-11-10 Aurigene Oncology Limited Spojevi i pripravci za liječenje hematoloških poremećaja
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
CN108107147B (zh) * 2017-08-23 2020-09-15 湖南省妇幼保健院 亚临床盆腔炎性疾病标志物及其用途
SG11202002386WA (en) 2017-10-31 2020-04-29 Curis Inc Compounds and compositions for treating hematological disorders
CN111763201A (zh) * 2020-03-03 2020-10-13 中国药科大学 苯并噻唑类化合物及医药用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323201B1 (en) * 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
IL151045A0 (en) * 2000-02-07 2003-04-10 Abbott Gmbh & Co Kg 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
WO2003030902A1 (en) * 2001-10-09 2003-04-17 Tularik Inc. Imidazole derivates as anti-inflammatory agents
WO2003035602A1 (fr) * 2001-10-25 2003-05-01 Sankyo Company, Limited Modulateurs lipidiques
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
AU2003257094A1 (en) * 2002-08-08 2004-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
US7553848B2 (en) * 2004-01-23 2009-06-30 Amgen Inc. Vanilloid receptor ligands and their use in treatments

Also Published As

Publication number Publication date
WO2007112914A3 (en) 2007-11-29
GB0606429D0 (en) 2006-05-10
EP2004617A2 (en) 2008-12-24
BRPI0709270A2 (pt) 2011-06-28
CN101415695A (zh) 2009-04-22
WO2007112914A2 (en) 2007-10-11
KR20080098443A (ko) 2008-11-07
RU2008142834A (ru) 2010-05-10
AU2007234022A1 (en) 2007-10-11
US20090170914A1 (en) 2009-07-02
JP2009531365A (ja) 2009-09-03
CA2644636A1 (en) 2007-10-11

Similar Documents

Publication Publication Date Title
MX2008012399A (es) Modulacion de cinasa de ceramida.
TNSN08372A1 (en) Heterocyclic amides for use as pharmaceuticals
MY143249A (en) 4-substituted pyrrolidin-2-ones and their use
NO20092415L (no) Heteromonocyklisk forbindelse og anvendelse derav
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
MY168201A (en) Agricultural And Horticultural Fungicidal Composition
MX2009007713A (es) Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
TW200716584A (en) Dihydrobenzofuran derivatives and uses thereof
MX2013006101A (es) Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos.
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
MY149648A (en) Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
TN2010000064A1 (en) Novel herbicides
MX2009013276A (es) Compuestos anti-inflamatorios de ciclobutenodiona sustituida.
MX2010001364A (es) Derivados de ciclopentandiona puenteados triciclicos como herbicidas.
TW200800962A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
AR081819A1 (es) Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades
MX2009008772A (es) Derivado piridil-triazolopirimidina o su sal, pesticida que lo contiene y proceso para su produccion.
MX2009008028A (es) Agentes antiparasitarios.
DK2060568T3 (da) Polymorfer af enantiomerisk ren erdostein
MX2010002246A (es) Nuevos herbicidas.
PA8787001A1 (es) " derivados de macrolactona"
GB2483195A (en) Novel uses
MX2011010358A (es) Derivados de 2-hidroxietil-1h-quinolin-2-ona y sus analogos azaisostericos con actividad antibacteriana.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal